Commercial stage medical device firm LumiThera has agreed to acquire modern visual electrophysiology medical devices provider Diopsys for an undisclosed sum.

As part of the agreement, Diopsys stockholders will secure stock in LumiThera, and Diopsys will operate as a wholly-owned subsidiary of LumiThera.

Diopsys’s modern visual electrophysiology medical devices will enable eye care professionals to analyse the complete visual pathway for visual and neuro-visual disorders.

The firm offers both visual evoked potential (VEP) and ERG vision testing technology.

Its product portfolio includes Diopsys NOVA, Diopsys ARGOS, and Diopsys RETINA PLUS ERG and VEP Vision Testing System product series, and the Enfant Paediatric VEP Vision Testing System.

Diopsys CEO Joe Fontanetta said: “Diopsys ERG testing is a powerful and quantitative diagnostic that can be coupled with LumiThera’s PBM treatments to characterize early patient benefits on visual function.”

The acquisition will enable LumiThera to add a complementary diagnosis and monitoring platform to its treatment platform using Photobiomodulation (PBM) for ocular disease and damage.

Electroretinography (ERG) is a diagnostic test designed to measure the electrical activity of the retina of the eye in response to a light stimulus.

Diopsys in combination with Diopsys is expected to have a significant ophthalmology/optometry customer base.

During the first quarter of this year, LumiThera has recruited 100 subjects in the US LIGHTSITE III dry Age-related Macular Degeneration (AMD) trial.

The company is continuing the trial to reach the 13-month efficacy timepoint for all patients, which is expected in the first quarter of next year.

At the starting of this year, LumiThera and Diospys revealed final positive topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients.

In the trial, a total of 23 eyes from 15 patients with Dry AMD were treated with PBM using the Valeda Light Delivery System. It assessed the Diospys NOVA ERG system.

According to the company, subjects demonstrated up to 12.8 ± 0.98 letter improvement in best corrected visual acuity (BCVA) at month six compared to baseline (BL) scores.

LumiThera president and CEO Clark Tedford said: “We are strong believers of treating degenerative disease early to slow the progression of vision-threatening disease. The synergy of these technologies makes sense on many levels and could optimize Valeda treatments.”

The deal is expected to be completed within a few months.